The potential of FLI1 as a therapeutic target in human autoimmune diseases such as systemic sclerosis and systemic lupus erythematosus has been proposed, and the loss of FLI1 in CD8+ T cells enhances immunity to tumors has also been reported [41, 45]. The gene discussed is CD8A; the disease is autoimmune disease.